Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | DBH | P09172 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15863955 | 0.98 | PNMT (0.60) | PNMTTAAR1IDO1ALDH1A1KDM4E | |
| SCHEMBL19839247 | 0.87 | PNMT (0.44) | PNMTTAAR1IDO1ALDH1A1KDM4E | |
| SCHEMBL30252677 | 0.81 | TAAR1 (0.63) | PNMTTAAR1IDO1ALDH1A1KDM4E | |
| SCHEMBL3124138 | 0.81 | TAAR1 (0.63) | PNMTTAAR1IDO1ALDH1A1KDM4E | |
| SCHEMBL19923207 | 0.80 | PNMT (0.39) | PNMTTAAR1IDO1ALDH1A1KDM4E | |
| SCHEMBL3302008 | 0.79 | PNMT (0.68) | PNMTTAAR1IDO1ALDH1A1KDM4E | |
| SCHEMBL29413238 | 0.79 | — | — | |
| SCHEMBL1821 | 0.79 | — | — | |
| SCHEMBL29925179 | 0.78 | TSHR (0.39) | PNMTTAAR1IDO1ALDH1A1TSHR | |
| SCHEMBL7183195 | 0.78 | PNMT (0.43) | PNMTTAAR1IDO1TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773934-A2 | NOVEL FIRE RETARDANTS | Bromine Compounds Ltd. (IL) | 2007-04-18 | — | — | EP | claimed |
| WO-2006006154-A2 | NOVEL FIRE RETARDANTS | BROMINE COMPOUNDS LTD. (IL) | 2006-01-19 | — | — | WO | claimed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025064534-A1 | SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-119490464-A | Preparation method of 1,2, 3-triazole compound and application thereof in antifungal field | 中国人民解放军海军军医大学 | 2025-02-21 | — | — | CN | disclosed |
| CN-118791436-A | 2-Aminopyrimidine derivative and preparation method and application thereof | 中国科学院上海药物研究所 | 2024-10-18 | — | — | CN | disclosed |
| EP-3760625-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | disclosed |
| CN-117143079-A | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-111699191-B | Heterocyclic compound and organic light-emitting device comprising same | 株式会社LG化学 | 2023-11-07 | — | — | CN | disclosed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | disclosed |
| US-4876376-A | Process for the halogenation, nitration and fluorination of aromatic derivatives | RHONE-POULENC SPECIALISTES CHIMIQUES (FR) | 1989-10-24 | — | — | US | disclosed |
| EP-0130876-B1 | PROCESS FOR THE SIMULTANEOUS HALOGENATION AND FLUORINATION OF AROMATIC COMPOUNDS | RHONE-POULENC CHIMIE (FR) | 1988-04-20 | — | — | EP | disclosed |
| EP-0130875-B1 | PROCESS FOR THE HALOGENATION-NITRATION FLUORINATION OF AROMATIC COMPOUNDS | RHONE-POULENC CHIMIE (FR) | 1987-07-22 | — | — | EP | disclosed |
| EP-0220810-A1 | Insecticidal ethers | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-05-06 | — | — | EP | disclosed |
| US-4575571-A | HALOGEN IN LIQUID HYDROGEN FLUORIDE | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1986-03-11 | — | — | US | disclosed |
| EP-0130876-A1 | Process for the simultaneous halogenation and fluorination of aromatic compounds | RHONE-POULENC CHIMIE (FR) | 1985-01-09 | — | — | EP | disclosed |
| EP-0130875-A1 | Process for the halogenation-nitration fluorination of aromatic compounds | RHONE-POULENC CHIMIE (FR) | 1985-01-09 | — | — | EP | disclosed |
| US-4208430-A | CARBAMIMIDOTHIOIC ACID PHENYLALKYL ESTERS | SMITHKLINE CORPORATION (US) | 1980-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | MRGPRX2, MRGPRX1, MRGPRX4 | PNMT 225/4885TAAR1 252/4885IDO1 2668/4885 |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | PNMT 4658/4885TAAR1 4109/4885IDO1 1942/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | PNMT 559/4885TAAR1 4600/4885IDO1 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.